Johnson & Johnson seeks FDA emergency authorization for booster shot

The company saw a “substantial increase” in immune response when booster of its COVID-19 vaccine was given six months after the first shot.

Johnson & Johnson on Tuesday said its seeking emergency authorization for a booster dose of its COVID-19 vaccine from the US Food and Drug Administration. 

“Our clinical program has found that a booster of our COVID-19 vaccine increases levels of protection for those who have received our single-shot vaccine to 94 percent,” said Dr. Mathai Mammen, global head of research and development at Johnson & Johnson, in a release. “At the same time, we continue to recognize that a single-shot COVID-19 vaccine that provides strong and long-lasting protection remains a crucial component to vaccinating the global population.”

Read Full Story


Leave a Reply

Your email address will not be published.